新辅助化疗对晚期乳腺癌患者T淋巴细胞亚群免疫功能的影响

目的探讨晚期乳腺患者化疗前后T淋巴细胞亚群免疫功能的变化及其与病情的关系。方法采用流式细胞术检测45例晚期乳腺癌患者化疗前后的血标本T淋巴细胞亚群免疫功能,并与体检健康者作比较。结果晚期乳腺癌患者治疗前后T淋巴细胞亚群免疫功能低于对照组(P<0.05)。治疗后,化疗有效者总T细胞(CD3 )、辅助或诱导T淋巴细胞(CD4 )、CD4 与CD8 比值均显著升高(P<0.01),细胞毒或抑制性T淋巴细胞(CD8 )降低(P<0.05);化疗无效者CD3 、CD4 、CD4 /CD8 显著降低(P<0.05,P<0.01),而CD8 升高(P<0.01)。结论晚期乳腺癌患者免疫功能低下,有效化疗能提高患者的T淋巴细胞亚群免疫功能,临床上对免疫功能的观察对乳腺癌患者的治疗和预后有一定的监测作用。

Effects of Neoadjuvant Chemotherapy on T-lymphocyte Subgroup Immunity in Patients with Advanced Breast Cancer

Objective To analyze the functional changes of T-lymphocyte subgroups before and after chemotherapy in patients with breast cancer.Methods The change of T-lymphocyte subgroups immunity were measured with the flow cytometry and receptor adhering method in healthy controls and in patients with advanced breast cancer before and after treatment.Results The function of T-lymphocyte subgroup immunity were significantly lower in advanced breast cancer patients before and after chemotherapy than that in control group(P<0.05).After chemotherapy,CD3 and CD4 cells and the ratio of CD4 /CD8 were higher in the effective group than those in pre-treatment samples(P<0.01),while CD8 cells were lower than those in pre-treatment samples(P<0.05).CD3 and CD4 cells and the ratio of CD4 /CD8 were lower in the ineffective group than those in pre-treatment samples(P<0.05,P<0.01),while CD8 cells were higher than those in pre-treatment samples(P<0.01).Conclusion The immunity was suppressed in the patients with advanced breast cancer and immunity of the patients can be improved by effective chemotherapy.T-lymphocyte subgroup analyses may be helpful in the monitoring of treatment results.